<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%">&nbsp;</DIV>

<DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular; margin: 9pt 0 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular; margin: 0; text-align: center"><B>__________________</B></P>

<P STYLE="font: 16pt/115% TimesNewRomanPSStd-Regular; margin: 6pt 0 0; text-align: center"><B>FORM S-8</B></P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular; margin: 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES ACT
OF 1933</B></P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular; margin: 0; text-align: center"><B>__________________</B></P>

<P STYLE="font: 16pt/115% TimesNewRomanPSStd-Regular; margin: 7pt 0 0; text-align: center"><B>ANAVEX LIFE SCIENCES CORP. </B></P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular; margin: 2pt 0 10pt; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">
    <P STYLE="font: 9pt TimesNewRomanPSStd-Bold; margin: 0; border-bottom: Black 0.5pt solid; text-align: center"><B>Nevada</B></P></TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 9pt TimesNewRomanPSStd-Bold; margin: 0; border-bottom: Black 0.5pt solid; text-align: center"><B>98-0608404</B></P></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 11pt Arial, Helvetica, Sans-Serif; padding-left: 10pt; text-indent: -10pt; text-align: center"><FONT STYLE="font-family: TimesNewRomanPSStd-Regular; font-size: 10pt"><B>(State or other jurisdiction of </B></FONT></TD>
    <TD STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: TimesNewRomanPSStd-Regular; font-size: 10pt"><B>(IRS Employer </B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 11pt Arial, Helvetica, Sans-Serif; padding-left: 10pt; text-indent: -10pt; text-align: center"><FONT STYLE="font-family: TimesNewRomanPSStd-Regular; font-size: 10pt"><B>incorporation or organization) </B></FONT></TD>
    <TD STYLE="font: 11pt Arial, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: TimesNewRomanPSStd-Regular; font-size: 10pt"><B>Identification Number) </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular; margin: 10pt 0 0; text-align: center"><B>51 West 52<SUP>nd</SUP> Street, 7<SUP>th</SUP>
Floor<BR>
New York, NY 10019-6163<BR>
Telephone: 1-844-689-3939<BR>
</B><I>(Address and Telephone Number of Principal Executive Offices)</I></P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular; margin: 4pt 0 0; text-align: center"><B>Christopher Missling, PhD<BR>
Chief Executive Officer<BR>
51 West 52<SUP>nd</SUP> Street, 7<SUP>th</SUP> Floor<BR>
New York, NY 10019-6163<BR>
Telephone: 1-844-689-3939<BR>
</B><I>(Name, Address and Telephone Number of Agent for Service)</I></P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular; margin: 0; text-align: center"><B>__________________</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Anavex Life Sciences Corp. 2007 Stock Option
Plan</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Anavex Life Sciences Corp. 2019 Omnibus Incentive
Plan</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center">(<I>Full Title of Plans</I>)</P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular; margin: 4pt 0 0; text-align: center"><I>Copies to:</I></P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular; margin: 4pt 0 0; text-align: center"><B>Clayton E. Parker, Esq.<BR>
John C. Scarborough, Jr., Esq.<BR>
<BR>
K&amp;L Gates LLP<BR>
200 South Biscayne Boulevard, Suite 3900<BR>
Miami, Florida 33131-2399<BR>
Telephone: (305) 539-3300<BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12pt TimesNewRomanPSStd-Regular; margin: 2.5pt 0 10pt; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an &quot;emerging growth company&quot;.
See definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo; and
&quot;emerging growth company&quot; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: TimesNewRomanPSStd-Regular; font-size: 10pt">Large accelerated filer </FONT></TD>
    <TD STYLE="width: 18%; text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: TimesNewRomanPSStd-Regular; font-size: 10pt">Smaller reporting company </FONT></TD>
    <TD STYLE="width: 17%; text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: TimesNewRomanPSStd-Regular; font-size: 10pt">Non-accelerated filer </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: TimesNewRomanPSStd-Regular; font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD>
    <TD STYLE="line-height: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 11pt/115% Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: TimesNewRomanPSStd-Regular; font-size: 10pt">(Do not check if a smaller</FONT></TD>
    <TD STYLE="width: 18%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 17%; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: TimesNewRomanPSStd-Regular; font-size: 10pt">reporting company)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="line-height: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 10pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has not elected to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&nbsp;&uml;</FONT><FONT STYLE="font-family: Wingdings"><B>&#168;</B></FONT></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 10pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 42%; border-top: black 2.25pt double; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt">
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
    <P STYLE="font: 8pt/92% Times New Roman, Times, Serif; margin: 0 0 4pt; text-align: center"><B>Title of Securities to be Registered</B></P></TD>
    <TD STYLE="width: 13%; border-top: black 2.25pt double; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt">
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount&nbsp;to</B></P>
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>be&nbsp;registered&nbsp;(1)</B></P></TD>
    <TD STYLE="width: 16%; border-top: black 2.25pt double; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt">
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Proposed&nbsp;maximum</B></P>
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Offering&nbsp;price</B></P>
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>per&nbsp;share </B></P></TD>
    <TD STYLE="width: 18%; border-top: black 2.25pt double; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt">
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Proposed&nbsp;maximum</B></P>
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>aggregate&nbsp;offering</B></P>
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>price </B></P></TD>
    <TD STYLE="width: 11%; border-top: black 2.25pt double; border-bottom: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt">
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount&nbsp;of</B></P>
    <P STYLE="font: 8pt/91% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>registration&nbsp;fee</B></P></TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; border-right: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt"><FONT STYLE="font-size: 8pt">Common stock, $0.001 par value per share, reserved for issuance pursuant to the Anavex Life Sciences Corp. 2019 Omnibus Incentive Plan</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; border-right: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt; text-align: center"><FONT STYLE="font-size: 8pt">6,000,000 (2)</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; border-right: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt; text-align: center"><FONT STYLE="font-size: 8pt">$15.18(3)</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; border-right: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt; text-align: center"><FONT STYLE="font-size: 8pt">$91,080,000.00</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 4.65pt; padding-left: 4.65pt; text-align: center"><FONT STYLE="font-size: 8pt">$ 9,936.83</FONT></TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; border-right: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt"><FONT STYLE="font-size: 8pt">Common stock, $0.001 par value per share, issuable pursuant to outstanding options granted under the Anavex Life Sciences Corp. Amended and Restated 2007 Stock Option Plan</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; border-right: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt; text-align: center"><FONT STYLE="font-size: 8pt">1,331,250 (4)</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; border-right: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt; text-align: center"><FONT STYLE="font-size: 8pt">$1.26 (5)</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; border-right: black 1pt solid; padding-right: 4.65pt; padding-left: 4.65pt; text-align: center"><FONT STYLE="font-size: 8pt">$1,677,375</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 4.65pt; padding-left: 4.65pt; text-align: center"><FONT STYLE="font-size: 8pt">$183.00</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right">(1)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration
statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting
from stock splits, stock dividends or similar transactions.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right">(2)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Represents 6,000,000 shares of common stock reserved for issuance pursuant to future awards,
and issuable pursuant to outstanding options, granted under the Anavex Life Sciences Corp. 2019 Omnibus Incentive Plan (the &ldquo;2019
Plan&rdquo;).</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right">(3)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c)
and (h) under the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the registrant&rsquo;s
common stock as reported on The NASDAQ Capital Market on April 8, 2021.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right">(4)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Represents 1,331,250 shares of common stock subject to outstanding stock options awards under
the Anavex Life Sciences Corp. Amended and Restated 2007 Stock Option Plan (the &ldquo;2007 Plan&rdquo;).</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right">(5)</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h)
under the Securities Act of 1933, as amended, and based on the weighted average exercise price of the outstanding options.</TD>
</TR></TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 4pt 0 0 13.5pt; text-indent: -13.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 4pt 0 0 13.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 1. Plan Information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">The information required by Item
1 is included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1)
of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 2. Registrant Information and Employee Plan
Annual Information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">The written statement required
by Item 2 is included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule
428(b)(1) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 3. Incorporation of Documents by Reference.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">The following documents have
been previously filed by Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
and are hereby incorporated by reference into this registration statement and shall be deemed a part hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.75in; text-align: justify">(a) The Annual Report of the
Company on Form 10-K for the fiscal year ended September 30, 2020, filed with the SEC on December 28, 2020;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.75in; text-align: justify">(b) The Quarterly Report of the
Company on Form 10-Q for the quarter ended December 31, 2020, filed with the SEC on February 16, 2021; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.75in; text-align: justify">(d) The description of the Common
Stock contained in the registration statement on Form 8-A (Registration No. 001-37606) filed with the SEC on October 23, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
reports and other documents subsequently filed by the registrant pursuant to sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange
Act of 1934, as amended</FONT><FONT STYLE="font-family: TimesNewRomanPSStd-Regular">, except for information furnished under Item 2.02
or 7.01 of Current Report on Form 8-K, or exhibits related thereto, </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">prior
to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities
then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the
date of the filing of such reports and documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">Any statement contained in a
document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded
for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document
which also is or is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified
or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Any Current
Report on Form 8-K that is furnished to the SEC but not filed with the SEC is not deemed incorporated by reference into this Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 4. Description of Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 5. Interests of Named Experts and Counsel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 6. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">Under
the Nevada Revised Statutes, director immunity from liability to a company or its stockholders for monetary liabilities applies automatically
unless it is specifically limited by a company&rsquo;s Articles of Incorporation.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; text-indent: 0.25in">Section 78.7502 of
the Nevada Revised Statutes permits a corporation to indemnify a present or former director, officer, employee or agent of the corporation,
or any person who is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, who was or is a party or is threatened to be made a party to any threatened, pending
or completed action, suit or proceeding, except an action by or in the right of the corporation, against expenses, including attorneys&rsquo;
fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with the action, suit
or proceeding if such person (1) is not liable pursuant to Section 78.138 of the Nevada Revised Statutes, which sets forth standards for
the conduct of directors and officers, or (2) acted in good faith and in a manner which he or she reasonably believed to be in or not
opposed to the best interests of the corporation and, with respect to a criminal action or proceeding, had no reasonable cause to believe
his or her conduct was unlawful.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; text-indent: 0.25in">Section 78.751 of
the Nevada Revised Statutes permits any discretionary indemnification under Section 78.7502 of the Nevada Revised Statutes, unless ordered
by a court or advanced to a director or officer by the corporation in accordance with the Nevada Revised Statutes, to be made by a corporation
only as authorized in each specific case upon a determination that indemnification of the director, officer, employee or agent is proper
in the circumstances. Such determination must be made (1) by the stockholders, (2) by the board of directors by majority vote of a quorum
consisting of directors who were not parties to the action, suit or proceeding, (3) if a majority vote of a quorum consisting of directors
who were not parties to the action, suit or proceeding so orders, by independent legal counsel in a written opinion, or (4) if a quorum
consisting of directors who were not parties to the action, suit or proceeding cannot be obtained, by independent legal counsel in a written
opinion. Section 78.751 of the Nevada Revised Statutes provide that the articles of incorporation, bylaws or an agreement made by a corporation
may provide that expenses of officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid
by a corporation as they are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking
by or on behalf of a director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that
a director or officer is not entitled to be indemnified by the corporation.</P>

<P STYLE="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 10pt 0 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Bylaws provide that we will indemnify, to the greatest allowable extent permitted under the Nevada Revised Statutes, directors or officers
of the Company for any duties or obligations arising o</FONT><FONT STYLE="font-family: TimesNewRomanPSStd-Regular">ut of any acts or conduct
of the officer or director performed for or on behalf of the Company. We will reimburse each such person for all expenses reasonably incurred
by him in connection with any such claim </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">or liability, including power
to defend such persons from all suits or claims, as provided for under the provisions of the Nevada Revised Statutes. In addition, our
Bylaws provide that the board of directors may cause the Company to purchase and maintain insurance on behalf of any person who is or
was a director or officer of the Company against any liability asserted against such person and incurred in any such capacity or arising
out of such status, whether or not the Corporation would have the power to indemnify such person.</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify; text-indent: 0.25in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company under
Nevada law or otherwise, the Company has been advised that the opinion of the SEC is that such indemnification is against public policy
as expressed in the Securities Act of 1933 and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">At present, there is no pending litigation or proceeding
involving any of our directors, officers or employees in which indemnification is sought, nor are we aware of any threatened litigation
that may result in claims for indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 7. Exemption from Registration Claimed.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8. Exhibits.</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description of Exhibit</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 11%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1314052/000113707005000007/ex41.htm" STYLE="-sec-extract: exhibit">Specimen Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company&rsquo;s Registration Statement on Form&nbsp;SB-2 filed on January 13, 2005)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex3-1.htm" STYLE="-sec-extract: exhibit">Articles of Incorporation of Anavex Life Sciences Corp. (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed with the SEC on May 9, 2019)</A></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm" STYLE="-sec-extract: exhibit">Bylaws of Anavex Life Sciences Corp. (incorporated by reference to Exhibit 3 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 28, 2007)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="e2594_ex5-1.htm">Opinion of Snell &amp; Wilmer, L.L.P.</A> </FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="e2594_ex231.htm">Consent of BDO USA, LLP</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="e2594_ex5-1.htm">Consent of Snell &amp; Wilmer, L.L.P. (incorporated from Exhibit 5.1)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A HREF="#a_01">Power of Attorney (included on signature page hereto)</A></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1314052/000161577419002242/s115994_def14a.htm" STYLE="-sec-extract: exhibit">Anavex Life Sciences Corp. 2019 Omnibus Incentive Plan (incorporated by reference to Annex B to the Company&rsquo;s Proxy Statement pursuant to Section 14(a) of the Exchange Act filed with the SEC on February 11, 2019)</A></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit99_1.htm" STYLE="-sec-extract: exhibit">Anavex Life Sciences Corp. 2007 Stock Option Plan (incorporated by reference to Exhibit 99.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 28, 2007)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1314052/000106299311000480/exhibit99-1.htm" STYLE="-sec-extract: exhibit">Anavex Life Sciences Corp. 2007 Amended and Restated Stock Option Plan (incorporated by reference to Exhibit 99.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on February 8, 2011)</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 9. Undertakings</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>1. </B>The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>(a) </B>To file, during any period
in which offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><B>(i) </B>To include
any prospectus required by section 10(a)(3) of the Securities Act;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><B>(ii) </B>To reflect in the prospectus
any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) (&sect; 230.424(b) of this chapter) if, in the aggregate, the changes
in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
Fee&rdquo; table in the effective registration statement.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><B>(iii) </B>To include any material
information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to
such information in the registration statement;</P>

<P STYLE="font: 11pt/115% Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>provided, however, </I>that paragraphs (a)(i)
and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in
reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to section 13 or section 15(d) of
the Exchange Act that are incorporated by reference in the registration statement.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>(b) </B>That, for the purpose of
determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>(c) </B>To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>2. </B>The undersigned registrant hereby undertakes
that, for purposes of determining any liability under the Securities Act, each filing of the registrant&rsquo;s annual report pursuant
to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report
pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a
new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>3. </B>Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<B>SIGNATURES</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
in the City of New York, State of New York, as of the 9th  day of April 2021.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 247.5pt"><B>ANAVEX LIFE SCIENCES CORP. </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 4in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Christopher Missling, PhD</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Principal </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Officer and Chairman of </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Board of Directors </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 4in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 4in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_01" TITLE="Power of Attorney"></A>POWER OF ATTORNEY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.6pt">We, the undersigned officers
and directors of Anavex Life Sciences Corp., do hereby constitute and appoint Christopher Missling, PhD our true and lawful attorney-in-fact
and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to
sign any and all amendments to this Registration Statement, and to file the same, with exhibits thereto, and other documents in connection
therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act
and thing requisite are necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in
person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or
cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Act of 1933, this registration statement has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated below:</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signatures</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 52%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title(s)</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 14%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Christopher Missling, PhD</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (Principal Executive Officer)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Sandra Boenisch, CPA, CGA</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer and Treasurer (Principal Accounting</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Athanasios Skarpelos</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Athanasios Skarpelos</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Claus van der Velden, PhD </I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claus van der Velden, PhD</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Elliot Favus, MD </I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elliot Favus, MD</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Steffen Thomas, PhD </I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steffen Thomas, PhD</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Peter Donhauser, D.O.</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 9, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Donhauser, D.O.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "e2594_s8.htm", "secsgml_size_bytes": 60151}]
{"company-data": {"conformed-name": "ANAVEX LIFE SCIENCES CORP.", "cik": "0001314052", "assigned-sic": "8731", "irs-number": "208365999", "state-of-incorporation": "NV", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-255166", "film-number": "21818485"}, "business-address": {"street1": "51 W 52ND STREET,", "street2": "7TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10019-6163", "phone": "800-689-3939"}, "mail-address": {"street1": "51 W 52ND STREET,", "street2": "7TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10019-6163"}, "former-company": {"former-conformed-name": "Thrifty Printing Inc.", "date-changed": "20050111"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT
OF 1933
__________________
ANAVEX LIFE SCIENCES CORP.
(Exact name of registrant as specified
in its charter)
Nevada
98-0608404
(State or other jurisdiction of
(IRS Employer
incorporation or organization)
Identification Number)
51 West 52
nd
Street, 7
th
Floor
New York, NY 10019-6163
Telephone: 1-844-689-3939
(Address and Telephone Number of Principal Executive Offices)
Christopher Missling, PhD
Chief Executive Officer
51 West 52
nd
Street, 7
th
Floor
New York, NY 10019-6163
Telephone: 1-844-689-3939
(Name, Address and Telephone Number of Agent for Service)
__________________
Anavex Life Sciences Corp. 2007 Stock Option
Plan
Anavex Life Sciences Corp. 2019 Omnibus Incentive
Plan
(
Full Title of Plans
)
Copies to:
Clayton E. Parker, Esq.
John C. Scarborough, Jr., Esq.
K&L Gates LLP
200 South Biscayne Boulevard, Suite 3900
Miami, Florida 33131-2399
Telephone: (305) 539-3300
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an "emerging growth company".
See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and
"emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
¨
Smaller reporting company
x
Non-accelerated filer
x
Emerging growth company
¨
Accelerated filer
¨
(Do not check if a smaller
reporting company)
If
an emerging growth company, indicate by checkmark if the registrant has not elected to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
¨
CALCULATION OF REGISTRATION FEE
Title of Securities to be Registered
Amount to
be registered (1)
Proposed maximum
Offering price
per share
Proposed maximum
aggregate offering
price
Amount of
registration fee
Common stock, $0.001 par value per share, reserved for issuance pursuant to the Anavex Life Sciences Corp. 2019 Omnibus Incentive Plan
6,000,000 (2)
$15.18(3)
$91,080,000.00
$ 9,936.83
Common stock, $0.001 par value per share, issuable pursuant to outstanding options granted under the Anavex Life Sciences Corp. Amended and Restated 2007 Stock Option Plan
1,331,250 (4)
$1.26 (5)
$1,677,375
$183.00
(1)
In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration
statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting
from stock splits, stock dividends or similar transactions.
(2)
Represents 6,000,000 shares of common stock reserved for issuance pursuant to future awards,
and issuable pursuant to outstanding options, granted under the Anavex Life Sciences Corp. 2019 Omnibus Incentive Plan (the "2019
Plan").
(3)
Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c)
and (h) under the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the registrant's
common stock as reported on The NASDAQ Capital Market on April 8, 2021.
(4)
Represents 1,331,250 shares of common stock subject to outstanding stock options awards under
the Anavex Life Sciences Corp. Amended and Restated 2007 Stock Option Plan (the "2007 Plan").
(5)
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h)
under the Securities Act of 1933, as amended, and based on the weighted average exercise price of the outstanding options.
2
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1. Plan Information.
The information required by Item
1 is included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1)
of the Securities Act of 1933, as amended (the "Securities Act").
Item 2. Registrant Information and Employee Plan
Annual Information.
The written statement required
by Item 2 is included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule
428(b)(1) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents have
been previously filed by Anavex Life Sciences Corp. (the "Company") with the Securities and Exchange Commission (the "SEC")
and are hereby incorporated by reference into this registration statement and shall be deemed a part hereof:
(a) The Annual Report of the
Company on Form 10-K for the fiscal year ended September 30, 2020, filed with the SEC on December 28, 2020;
(b) The Quarterly Report of the
Company on Form 10-Q for the quarter ended December 31, 2020, filed with the SEC on February 16, 2021; and
(d) The description of the Common
Stock contained in the registration statement on Form 8-A (Registration No. 001-37606) filed with the SEC on October 23, 2015.
All
reports and other documents subsequently filed by the registrant pursuant to sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange
Act of 1934, as amended
, except for information furnished under Item 2.02
or 7.01 of Current Report on Form 8-K, or exhibits related thereto,
prior
to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities
then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the
date of the filing of such reports and documents.
Any statement contained in a
document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded
for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document
which also is or is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified
or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Any Current
Report on Form 8-K that is furnished to the SEC but not filed with the SEC is not deemed incorporated by reference into this Registration
Statement.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel
Not applicable.
3
Item 6. Indemnification of Directors and Officers.
Under
the Nevada Revised Statutes, director immunity from liability to a company or its stockholders for monetary liabilities applies automatically
unless it is specifically limited by a company's Articles of Incorporation.
Section 78.7502 of
the Nevada Revised Statutes permits a corporation to indemnify a present or former director, officer, employee or agent of the corporation,
or any person who is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, who was or is a party or is threatened to be made a party to any threatened, pending
or completed action, suit or proceeding, except an action by or in the right of the corporation, against expenses, including attorneys'
fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with the action, suit
or proceeding if such person (1) is not liable pursuant to Section 78.138 of the Nevada Revised Statutes, which sets forth standards for
the conduct of directors and officers, or (2) acted in good faith and in a manner which he or she reasonably believed to be in or not
opposed to the best interests of the corporation and, with respect to a criminal action or proceeding, had no reasonable cause to believe
his or her conduct was unlawful.
Section 78.751 of
the Nevada Revised Statutes permits any discretionary indemnification under Section 78.7502 of the Nevada Revised Statutes, unless ordered
by a court or advanced to a director or officer by the corporation in accordance with the Nevada Revised Statutes, to be made by a corporation
only as authorized in each specific case upon a determination that indemnification of the director, officer, employee or agent is proper
in the circumstances. Such determination must be made (1) by the stockholders, (2) by the board of directors by majority vote of a quorum
consisting of directors who were not parties to the action, suit or proceeding, (3) if a majority vote of a quorum consisting of directors
who were not parties to the action, suit or proceeding so orders, by independent legal counsel in a written opinion, or (4) if a quorum
consisting of directors who were not parties to the action, suit or proceeding cannot be obtained, by independent legal counsel in a written
opinion. Section 78.751 of the Nevada Revised Statutes provide that the articles of incorporation, bylaws or an agreement made by a corporation
may provide that expenses of officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid
by a corporation as they are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking
by or on behalf of a director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that
a director or officer is not entitled to be indemnified by the corporation.
Our
Bylaws provide that we will indemnify, to the greatest allowable extent permitted under the Nevada Revised Statutes, directors or officers
of the Company for any duties or obligations arising o
ut of any acts or conduct
of the officer or director performed for or on behalf of the Company. We will reimburse each such person for all expenses reasonably incurred
by him in connection with any such claim
or liability, including power
to defend such persons from all suits or claims, as provided for under the provisions of the Nevada Revised Statutes. In addition, our
Bylaws provide that the board of directors may cause the Company to purchase and maintain insurance on behalf of any person who is or
was a director or officer of the Company against any liability asserted against such person and incurred in any such capacity or arising
out of such status, whether or not the Corporation would have the power to indemnify such person.
Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company under
Nevada law or otherwise, the Company has been advised that the opinion of the SEC is that such indemnification is against public policy
as expressed in the Securities Act of 1933 and is, therefore, unenforceable.
At present, there is no pending litigation or proceeding
involving any of our directors, officers or employees in which indemnification is sought, nor are we aware of any threatened litigation
that may result in claims for indemnification.
Item 7. Exemption from Registration Claimed.
Not applicable.
4
Item 8. Exhibits.
Exhibit No.
Description of Exhibit
4.1
Specimen Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form SB-2 filed on January 13, 2005)
4.2
Articles of Incorporation of Anavex Life Sciences Corp. (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed with the SEC on May 9, 2019)
4.3
Bylaws of Anavex Life Sciences Corp. (incorporated by reference to Exhibit 3 to the Company's Current Report on Form 8-K filed with the SEC on September 28, 2007)
5.1
Opinion of Snell & Wilmer, L.L.P.
23.1
Consent of BDO USA, LLP
23.2
Consent of Snell & Wilmer, L.L.P. (incorporated from Exhibit 5.1)
24.1
Power of Attorney (included on signature page hereto)
99.1
Anavex Life Sciences Corp. 2019 Omnibus Incentive Plan (incorporated by reference to Annex B to the Company's Proxy Statement pursuant to Section 14(a) of the Exchange Act filed with the SEC on February 11, 2019)
99.2
Anavex Life Sciences Corp. 2007 Stock Option Plan (incorporated by reference to Exhibit 99.1 to the Company's Current Report on Form 8-K filed with the SEC on September 28, 2007)
99.3
Anavex Life Sciences Corp. 2007 Amended and Restated Stock Option Plan (incorporated by reference to Exhibit 99.1 to the Company's Current Report on Form 8-K filed with the SEC on February 8, 2011)
5
Item 9. Undertakings
1.
The undersigned registrant hereby undertakes:
(a)
To file, during any period
in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
To include
any prospectus required by section 10(a)(3) of the Securities Act;
(ii)
To reflect in the prospectus
any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) (§ 230.424(b) of this chapter) if, in the aggregate, the changes
in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration
Fee" table in the effective registration statement.
(iii)
To include any material
information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to
such information in the registration statement;
provided, however,
that paragraphs (a)(i)
and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in
reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to section 13 or section 15(d) of
the Exchange Act that are incorporated by reference in the registration statement.
(b)
That, for the purpose of
determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.
(c)
To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
2.
The undersigned registrant hereby undertakes
that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant
to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report
pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a
new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
3.
Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
6
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
in the City of New York, State of New York, as of the 9th  day of April 2021.
ANAVEX LIFE SCIENCES CORP.
By:
/s/ Christopher Missling, PhD
Name:
Christopher Missling, PhD
Title:
Chief Executive Officer, Principal
Executive Officer and Chairman of
the Board of Directors
7
POWER OF ATTORNEY
We, the undersigned officers
and directors of Anavex Life Sciences Corp., do hereby constitute and appoint Christopher Missling, PhD our true and lawful attorney-in-fact
and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to
sign any and all amendments to this Registration Statement, and to file the same, with exhibits thereto, and other documents in connection
therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act
and thing requisite are necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in
person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or
cause to be done by virtue hereof.
Pursuant to the requirements
of the Securities Act of 1933, this registration statement has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated below:
Signatures
Title(s)
Date
/s/ Christopher Missling, PhD
Chief Executive Officer (Principal Executive Officer)
April 9, 2021
Christopher Missling, PhD
/s/ Sandra Boenisch, CPA, CGA
Principal Financial Officer and Treasurer (Principal Accounting
April 9, 2021
Sandra Boenisch, CPA, CGA
Officer)
/s/ Athanasios Skarpelos
Director
April 9, 2021
Athanasios Skarpelos
/s/ Claus van der Velden, PhD
Director
April 9, 2021
Claus van der Velden, PhD
/s/ Elliot Favus, MD
Director
April 9, 2021
Elliot Favus, MD
/s/ Steffen Thomas, PhD
Director
April 9, 2021
Steffen Thomas, PhD
/s/ Peter Donhauser, D.O.
Director
April 9, 2021
Peter Donhauser, D.O.
8